Diabetic Neuropathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Diabetic Neuropathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Neuropathy - Drugs In Development, 2022, provides an overview of the Diabetic Neuropathy (Metabolic Disorders) pipeline landscape.

Diabetic neuropathy, a common complication of diabetes, is damage to the nerves that allow feeling things such as pain. Symptoms include tingling, numbness, burning and pain. The predisposing factors are obesity, hypertension, high lipid and sugar levels, smoking, etc. It may be managed by medication and dietary modification.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Neuropathy - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Diabetic Neuropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Neuropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 8, 7, 18 and 6 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Diabetic Neuropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Neuropathy (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Diabetic Neuropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Diabetic Neuropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Diabetic Neuropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Neuropathy (Metabolic Disorders)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Diabetic Neuropathy (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Diabetic Neuropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Diabetic Neuropathy – Overview
Diabetic Neuropathy – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Diabetic Neuropathy – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Diabetic Neuropathy – Companies Involved in Therapeutics Development
Achelios Therapeutics Inc
Applied Therapeutics Inc
Beijing Tide Pharmaceutical Co Ltd
Bexion Pharmaceuticals LLC
Celon Pharma SA
CSPC Pharmaceutical Group Ltd
Epigen Biosciences Inc
Exodos Life Sciences Limited Partnership
Frontbio Co Ltd
G&P Bioscience Co Ltd
Glycadia Inc
Grunenthal GmbH
Han Wha Pharma Co Ltd
Ion Channel Pharmacology LLC
JanOne Inc
Korea United Pharm Inc
Medifron DBT Co Ltd
Mitsubishi Tanabe Pharma Corp
Omeros Corp
Ono Pharmaceutical Co Ltd
Palisade Bio, Inc
Praetego Inc
Pure Green Pharmaceuticals Inc
Reata Pharmaceuticals Inc
Releviate Therapeutics
Shandong Huizhi Pharmaceutical Technology Co Ltd
Sichuan Haisco Pharmaceutical Co Ltd
Sonnet BioTherapeutics Holdings Inc
WEX Pharmaceuticals Inc
Winsantor Inc
Zelira Therapeutics Ltd
Zhejiang Pharmaceutical Co Ltd
Diabetic Neuropathy – Drug Profiles
A-717 – Drug Profile
atexakin alfa – Drug Profile
BXQ-350 – Drug Profile
caficrestat – Drug Profile
CPL-207280CA – Drug Profile
elismetrep – Drug Profile
EPGN-2154 – Drug Profile
FB-118B1 – Drug Profile
GB-102 – Drug Profile
GLY-230 – Drug Profile
HSK-16149 – Drug Profile
ketoprofen – Drug Profile
KU-32 – Drug Profile
lidocaine – Drug Profile
MDR-16523 – Drug Profile
MDR-652 – Drug Profile
Monoclonal Antibodies to Inhibit MASP-2 for Diabetic Complications and Rheumatoid Arthritis – Drug Profile
NSI-189 – Drug Profile
ONO-2910 – Drug Profile
Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Male Health – Drug Profile
PGDN-20WS – Drug Profile
pirenzepine – Drug Profile
PTG-6 – Drug Profile
PTG-640 – Drug Profile
PTG-641 – Drug Profile
resiniferatoxin – Drug Profile
RLVT-1402 – Drug Profile
RLVT-903 – Drug Profile
RTA-901 – Drug Profile
Small Molecule for Algodystrophy, Chemotherapy Induced Peripheral Neuropathy, Diabetic Peripheral Neuropathy and Pain – Drug Profile
Small Molecule for Diabetic Peripheral Neuropathy – Drug Profile
Small Molecule to Agonize MOR1 for Chemotherapy Induced Peripheral Neuropathy, Diabetic Peripheral Neuropathy and Postherpetic Neuralgia – Drug Profile
Small Molecules to Agonize CB1 and CB2 for Diabetic Neuropathy and Peripheral Arterial Disease – Drug Profile
Small Molecules to Target Plasminogen for Chronic Inflammatory Diseases and Diabetic Neuropathy – Drug Profile
sodium nitrite SR – Drug Profile
SYHA-1402 – Drug Profile
Tetrodotoxin – Drug Profile
UI-016 – Drug Profile
UI-048 – Drug Profile
YJ-001 – Drug Profile
YJC-007 – Drug Profile
Diabetic Neuropathy – Dormant Projects
Diabetic Neuropathy – Discontinued Products
Diabetic Neuropathy – Product Development Milestones
Featured News & Press Releases
Aug 02, 2021: Innovative drug HSK16149 capsule was approved to carry out phase II clinical trial of auxiliary opioid analgesia
Jun 02, 2021: Innovative drug HSK16149 capsule new indications obtained IND application Notice of Acceptance
May 13, 2021: Pure Green Pharmaceuticals reports unexpected results of a randomized, placebo controlled clinical trial with sublingual CBD in patients with painful diabetic peripheral neuropathy
Apr 01, 2021: Celon Pharma announces CPL’280, second generation oral GPR40 agonist, meets primary endpoint in phase 1 trial
Jan 25, 2021: Sonnet BioTherapeutics announces the successful completion of a non-human primate toxicology study of SON-080
Sep 30, 2020: Praetego receives NIH phase 2 STTR funding to advance novel amadorin drug candidates for diabetic peripheral neuropathy
Apr 12, 2019: “SYHA1402” for the treatment of diabetic neuropathy was granted clinical trial approval
Jun 01, 2018: Reata Selected to Present on its Early-Stage Program RTA 901 at the BIO International Convention
Mar 16, 2018: Reata to Present on its Diabetic Neuropathy Drug Candidate RTA-901 at the BIO Asia International Conference
Aug 02, 2017: Neuralstem Awarded $~1MM Grant by NIH to Continue Preclinical Research into the Potential of NSI-189 for Treatment of Diabetic Neuropathy
Sep 04, 2016: Salvianolic acid A tablets developed by the National Drug Screening Center received clinical approval
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development for Diabetic Neuropathy, 2022
Table 2: Number of Products under Development by Companies, 2022
Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
Table 4: Number of Products under Development by Universities/Institutes, 2022
Table 5: Products under Development by Companies, 2022
Table 6: Products under Development by Companies, 2022 (Contd..1)
Table 7: Products under Development by Companies, 2022 (Contd..2)
Table 8: Products under Development by Universities/Institutes, 2022
Table 9: Number of Products by Stage and Target, 2022
Table 10: Number of Products by Stage and Mechanism of Action, 2022
Table 11: Number of Products by Stage and Route of Administration, 2022
Table 12: Number of Products by Stage and Molecule Type, 2022
Table 13: Diabetic Neuropathy – Pipeline by Achelios Therapeutics Inc, 2022
Table 14: Diabetic Neuropathy – Pipeline by Applied Therapeutics Inc, 2022
Table 15: Diabetic Neuropathy – Pipeline by Beijing Tide Pharmaceutical Co Ltd, 2022
Table 16: Diabetic Neuropathy – Pipeline by Bexion Pharmaceuticals LLC, 2022
Table 17: Diabetic Neuropathy – Pipeline by Celon Pharma SA, 2022
Table 18: Diabetic Neuropathy – Pipeline by CSPC Pharmaceutical Group Ltd, 2022
Table 19: Diabetic Neuropathy – Pipeline by Epigen Biosciences Inc, 2022
Table 20: Diabetic Neuropathy – Pipeline by Exodos Life Sciences Limited Partnership, 2022
Table 21: Diabetic Neuropathy – Pipeline by Frontbio Co Ltd, 2022
Table 22: Diabetic Neuropathy – Pipeline by G&P Bioscience Co Ltd, 2022
Table 23: Diabetic Neuropathy – Pipeline by Glycadia Inc, 2022
Table 24: Diabetic Neuropathy – Pipeline by Grunenthal GmbH, 2022
Table 25: Diabetic Neuropathy – Pipeline by Han Wha Pharma Co Ltd, 2022
Table 26: Diabetic Neuropathy – Pipeline by Ion Channel Pharmacology LLC, 2022
Table 27: Diabetic Neuropathy – Pipeline by JanOne Inc, 2022
Table 28: Diabetic Neuropathy – Pipeline by Korea United Pharm Inc, 2022
Table 29: Diabetic Neuropathy – Pipeline by Medifron DBT Co Ltd, 2022
Table 30: Diabetic Neuropathy – Pipeline by Mitsubishi Tanabe Pharma Corp, 2022
Table 31: Diabetic Neuropathy – Pipeline by Omeros Corp, 2022
Table 32: Diabetic Neuropathy – Pipeline by Ono Pharmaceutical Co Ltd, 2022
Table 33: Diabetic Neuropathy – Pipeline by Palisade Bio, Inc, 2022
Table 34: Diabetic Neuropathy – Pipeline by Praetego Inc, 2022
Table 35: Diabetic Neuropathy – Pipeline by Pure Green Pharmaceuticals Inc, 2022
Table 36: Diabetic Neuropathy – Pipeline by Reata Pharmaceuticals Inc, 2022
Table 37: Diabetic Neuropathy – Pipeline by Releviate Therapeutics, 2022
Table 38: Diabetic Neuropathy – Pipeline by Shandong Huizhi Pharmaceutical Technology Co Ltd, 2022
Table 39: Diabetic Neuropathy – Pipeline by Sichuan Haisco Pharmaceutical Co Ltd, 2022
Table 40: Diabetic Neuropathy – Pipeline by Sonnet BioTherapeutics Holdings Inc, 2022
Table 41: Diabetic Neuropathy – Pipeline by WEX Pharmaceuticals Inc, 2022
Table 42: Diabetic Neuropathy – Pipeline by Winsantor Inc, 2022
Table 43: Diabetic Neuropathy – Pipeline by Zelira Therapeutics Ltd, 2022
Table 44: Diabetic Neuropathy – Pipeline by Zhejiang Pharmaceutical Co Ltd, 2022
Table 45: Diabetic Neuropathy – Dormant Projects, 2022
Table 46: Diabetic Neuropathy – Dormant Projects, 2022 (Contd..1)
Table 47: Diabetic Neuropathy – Dormant Projects, 2022 (Contd..2)
Table 48: Diabetic Neuropathy – Dormant Projects, 2022 (Contd..3)
Table 49: Diabetic Neuropathy – Discontinued Products, 2022
List of Figures
Figure 1: Number of Products under Development for Diabetic Neuropathy, 2022
Figure 2: Number of Products under Development by Companies, 2022
Figure 3: Number of Products by Top 10 Targets, 2022
Figure 4: Number of Products by Stage and Top 10 Targets, 2022
Figure 5: Number of Products by Top 10 Mechanism of Actions, 2022
Figure 6: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Figure 7: Number of Products by Routes of Administration, 2022
Figure 8: Number of Products by Stage and Routes of Administration, 2022
Figure 9: Number of Products by Molecule Types, 2022
Figure 10: Number of Products by Stage and Molecule Types, 2022

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings